-+ 0.00%
-+ 0.00%
-+ 0.00%

Sol-Gel Announces Product Purchase Agreement With Mayne Pharma's Unit For Sale And Exclusive License Of U.S. Rights To EPSOLAY and TWYNEO; Sol-Gel to Receive $16M During 2025

Benzinga·04/17/2025 12:45:39
Listen to the news
  • Sol-Gel to receive $16 million during 2025
  • Cash runway is expected to extend into the first quarter of 2027; Company expects to have sufficient cash to complete its Phase III clinical trial
  • SGT-610 Phase III clinical trial top-line results are expected in the fourth quarter of 2026; a significant milestone in the clinical trial of recruiting more than 80% of the patients has been achieved
  • Sol-Gel now estimates the U.S. market potential for SGT-610 to be between $400 to $500 million annually
  • SGT-210 Phase 1b trial in Darier patients is ongoing; 50% of the patients have already completed the trial

NESS ZIONA, Israel, April 17, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL), a clinical-stage dermatology company, today announced it has entered into a product purchase agreement with a subsidiary of Mayne Pharma Group Limited (ASX: MYX) (Mayne Pharma) for the sale and exclusive license of the U.S. rights to EPSOLAY and TWYNEO. Under the terms of the agreement, Sol-Gel will receive a total of $16 million in two installments: $10 million in the second quarter of 2025 and $6 million in the fourth quarter of 2025, which is expected to extend the Company's cash runway into the first quarter of 2027. This agreement was executed following the mutual termination by Sol-Gel and Galderma of the exclusive five-year license agreement in the U.S. for both products.